Define what “yield” means before screening
For a recombinant antibody, an upstream culture titer, total affinity-capture recovery and final purified mass are different quantities. Sequence candidates that look favorable in one measurement may perform poorly after clarification, capture, polishing or buffer exchange. Compare the usable material recovered at a defined quality level, not just the amount expressed before purification.
Choose the production route based on format and intended biology: a mammalian platform is commonly used for IgG-like molecules, while bacterial or other systems may suit selected VHH constructs. Host-dependent folding, glycosylation and other post-translational features can make results non-transferable. The manufacturing system ultimately required for a product should be considered separately from a research screening host.
A practical small-scale production scorecard
| Stage | What to record | Why it matters |
|---|---|---|
| Sequence and construct | Exact version, tags, signal peptide, chains, predicted mass | Prevents confounding between sequence and construct design |
| Expression | Host, scale, collection time, assay method, crude titer if measured | Separates expression biology from downstream losses |
| Capture and polishing | Resin / affinity method, recovered mass, buffer and step recovery | Locates loss and possible purification-related liabilities |
| Identity and purity | Appropriate gel / CE / mass assessment as feasible | Distinguishes target product from contaminants or fragments |
| Physical state | SEC monomer and higher-molecular-weight species | Tests whether recovered mass is in a useful form |
| Binding | SPR/BLI or suitable functional check on purified material | Confirms that the produced sample supports the original hypothesis |
Screening methods should be fit for purpose. A full characterization panel may not be economical or necessary for every early hit.
Common interpretation traps
- Titer is not recovery: a high upstream titer can be offset by poor purification behavior or aggregation.
- Purity is not identity: a strong band at the expected molecular weight does not establish the complete intended molecular species.
- Small-scale yield is not commercial manufacturability: different hosts, vectors and process scales can change performance.
- Batch variation is not sequence variation: include assay references and comparable culture conditions across a sequence panel.
- Protein present is not protein active: check target binding or functional behavior using the final prepared sample.
What to request from an external laboratory
Ask for a chain of material accounting from expression through the final aliquots. Specify what constitutes delivered usable material: concentration, total amount, volume, buffer, purity/SEC evidence and binding suitability. State which measurements are exploratory and which determine advancement. Require reported deviations when a construct cannot be recovered within the agreed screening conditions.
For AI-driven campaigns, consider a staged process: a broad low-material feasibility pass, then purification and orthogonal characterization for a narrower set of candidates. Discuss viable assay order, host selection and material needs in a non-confidential scope before exchanging proprietary sequences.
See the VHH-specific evaluation guide, aggregation and thermal-stability methods, and assay overview.
Scientific context
- Expression of Recombinant Antibodies (2013)
- Developability assessment at early-stage discovery (2023)
Background reading; links do not imply endorsement or a service partnership.